Agennix raises €76 million
This article was originally published in Scrip
Executive Summary
Raising substantial sums of money is always easier when a company has a wealthy benefactor supporting its aims. Agennix, the German cancer research company, has raised €76 million through a rights and subscription issue that was heavily backed by dievini Hopp BioTech Holding, the life sciences-focused investment business. The funds will be used mainly to finance the company's Phase III trials of talactoferrin, the company's recombinant human lactoferrin.